Breaking Research News from sources other than Breastcancer.org

marijen

Yes, we used to live very close to Monsanto field. This is pretty interesting -

Media Advisory

Friday, July 20, 2018

NIH Clinical Center releases dataset of 32,000 CT images

https://www.nih.gov/news-events/news-releases/nih-...

marijen

Guidelines Conflict for Long-Term Opioid Tx in Cancer Survivors

https://www.empr.com/news/cdc-oncology-clinicians-...

Lumpie

Breast Cancer Treatment and Its Effects on Aging

https://www.practiceupdate.com/C/71685/56?elsca1=e...

Published in Journal of Geriatric Oncology

• This review looks at breast cancer survival in the context of accelerated aging.
• Evidence suggests an increased rate of physical and cognitive decline in women who have been treated for breast cancer that may be associated with the effect that the treatments have on normal cellular function.

{This probably doesn't surprise most of us!}

Lumpie

Breast Cancer Screening Using Tomosynthesis or Mammography

https://www.practiceupdate.com/C/72026/56?elsca1=e...

Published in Journal of the National Cancer Institute

• This was systematic review and meta-analysis of 17 studies with 1,009,790 participants comparing tomosynthesis vs 2D mammography for the screening of asymptomatic women with breast cancer. Incremental cancer detection rates were significantly higher in European/Scandinavian studies, wherein the participants had both tests (2.4 per 1000 screenings) compared with US studies in which the participants had one test or the other (1.1 per 1000 screenings). The recall rate with tomosynthesis was significantly lower than with mammography in US studies.
• Results show that cancer detection rates and recall rates are better with tomosynthesis. However, the improvements with tomosynthesis appear to be related to setting, with improved cancer detection rates in European/Scandinavian settings and reduction in recall rates in the US.

Lumpie

One-Stage Implant-Based Breast Reconstruction With an Acellular Dermal Matrix vs Two-Stage Breast Reconstruction

Published in The Lancet Oncology

https://www.practiceupdate.com/C/72025/56?elsca1=e...

• This randomized, controlled trial evaluated quality-of-life outcomes among women undergoing one-stage implant-based breast reconstruction with an acellular dermal matrix vs two-stage breast reconstruction. Overall, 8 hospitals in the Netherlands were involved in the study; the one-stage group included 60 patients and 61 patients were included in the two-stage group.
• Patient-reported quality-of-life outcomes were not better with a one-stage procedure, and risks for adverse outcomes were significantly higher.

Lumpie

Talazoparib Beneficial in Patients With Advanced Breast Cancer {and germline BRCA1/2 mutation}

https://www.practiceupdate.com/C/72170/56?elsca1=e...

Original source: published online Aug. 15 in the New England Journal of Medicine.

Single-agent talazoparib provides significant benefit over standard chemotherapy for patients with advanced breast cancer and germline BRCA1/2 mutation, according to a study... Outcomes reported by patients favored talazoparib, with significant overall improvements and significant delays noted in the time to clinically meaningful deterioration according to the global health status-quality-of-life and breast symptoms scales.

"Talazoparib resulted in a significantly longer progression-free survival than standard-of-care chemotherapy,"

Lumpie

Symptom Cluster of Emotional Distress, Fatigue, and Cognitive Difficulties Among Young and Older Breast Cancer Survivors

https://www.practiceupdate.com/c/71986/67/13/?elsc...

Original source: Journal of Geriatric Oncology

• This study enrolled 170 breast cancer survivors 1 to 12 months post chemotherapy with stage I–III disease to examine the nature of the symptom cluster of emotional distress, fatigue, and cognitive problems. The authors also assessed the mediating role of subjective stress and coping strategies (emotional control and meaning-focused coping) in the association between age and symptom cluster.
• The authors found that lower levels of subjective stress, but not coping strategies, mediated the association of age with the symptom cluster of emotional distress, fatigue, and cognitive difficulty and concluded that further research is needed to explore differences in subjective stress by age.

MuddlingThrough

Thanks Lumpie, I've never heard of Talazoparib, so will be watching this.

(Not sure why this duplicated three times ? ?)

MuddlingThrough

Thanks Lumpie, I've never heard of Talazoparib, so will be watching this.

MuddlingThrough

Thanks Lumpie, I've never heard of Talazoparib, so will be watching this.

marijen

Do Antidepressants Work?

https://www.madinamerica.com/2018/03/do-antidepres...

marijen

Saving money on Breast Cancer Screening..

Breast Cancer Screening Only for Women at Higher Risk

Nick Mulcahy

July 05, 2018

https://www.medscape.com/viewarticle/898924

marijen

Another way to save on us, let the PCP follow-up.

Breast Cancer Survivors: Transition to PCP Leads to Savings

Roxanne Nelson, RN, BSN

February 22, 2018

https://www.medscape.com/viewarticle/892989

Chemokaze

http://flip.it/encRmC

Apelisib - New targeted drug for hormone positive, Her 2 negative breast cancer

Lumpie

Association of Breast and Ovarian Cancers With Predisposition Genes Identified by Large-Scale Sequencing

Published in: JAMA Oncology

https://www.practiceupdate.com/C/72231/56?elsca1=e...

• In this study assessing whole-exome sequencing results from 11,416 patients with breast cancer, ovarian cancer, or both and 3988 controls, an increased risk of breast cancer was associated with PALB2, ATM, CHEK2, and MSH6 genes, whereas MSH6, RAD51C, TP53, and ATM genes were associated with an increased risk of ovarian cancer.
• In addition to confirming several well-known breast or ovarian cancer gene associations, this study identified MSH6 and ATM as possible moderate-risk breast and ovarian cancer predisposition genes, respectively.

Lumpie

Meaningful Activity of Poziotinib in HER2+ MBC After ≥2 Prior HER2-Directed Regimens

Published in: International Journal of Cancer

https://www.practiceupdate.com/c/71250/67/13/?elsc...

• In this open-label, multicenter phase II study, 106 patients with HER2-positive metastatic breast cancer were treated with 12 mg poziotinib once daily on a 14-day on/7-day off schedule. After a median follow-up of 12 months, the median progression-free and overall survival were 4.04 months and not reached, respectively. Frequently reported treatment-related adverse events were diarrhea, stomatitis, and rashes.
• These findings highlight the need for biomarker studies to support further investigation of poziotinib.

Lumpie

Hypnosis Doesn't Cut Post-Op Pain in Breast Cancer Surgery

Those who perceived that they received hypnosis had significantly reduced fatigue and anxiety

Published in: HealthDay

https://www.practiceupdate.com/C/72402/56?elsca1=e...

marijen

Cure Magazine - best article on Thyroid Nodules

https://www.curetoday.com/publications/cure/2018/s...

marijen

Prmary breast cancer can 'shut down its own spread'

Published Today

By Ana Sandoiu

Fact checked by Jasmin Collier

https://www.medicalnewstoday.com/articles/322898.p...

Lumpie

marijen, I wish I could give your "oh, really?" post a thumbs up! Love the pic and that title sounds tauntingly optimistic.

The idea of the immune system stopping cancer is certainly encouraging, but I think that we already knew that the immune system is often able to stops cancer - or we would see advanced cases much more often. According to the article "By some estimates, less than 0.02 percent of breakaway cells will form secondary tumors." So, 'bless their hearts,' our hard-working immune systems are already 99.98% effective. The article suggests that certain types of immune responses may be more effective and that perhaps that type of response could be encouraged or enhanced. This may represent a therapeutic opportunity. I certainly hope so!

Chemokaze

https://www.mskcc.org/blog/scientists-find-cancer-drivers-hiding-rna-not-dna

Lumpie

Thanks for the excellent link to the MSKCC research, Chemokaze. Fascinating! Here are highlights for those who need a synopsis:

In a Twist, Scientists Find Cancer Drivers Hiding in RNA, Not DNA

Researchers at the Sloan Kettering Institute have found that changes in an information-carrying molecule called messenger RNA can inactivate tumor-suppressing proteins and thereby promote cancer. The findings pinpoint previously unknown drivers of the disease.

...between DNA and proteins is another layer of information, called messenger RNA (mRNA), which serves as a crucial link between the two. New research suggests that mRNA itself may carry cancer-causing changes. And, because genetic tests don't usually look at mRNA, those changes have so far gone undetected by cancer doctors. "But these mRNA changes have the same ultimate effect as known cancer drivers in DNA, so we believe they may play a very important role."

Christine Mayr, a molecular biologist at the Sloan Kettering Institute is the senior author of a new paper on the topic published today in Nature. (Monday, August 27, 2018)

https://www.mskcc.org/blog/scientists-find-cancer-...

WC3

Lumpie:

Not just the coffee. They have put these warnings up in the bread and canned black olive section of the supermarket as well.

Lumpie

Survival of De Novo Stage IV HER2+ Breast Cancers Treated With HER2-Targeted Therapy

https://www.practiceupdate.com/c/72529/67/13/?elsc...

Published in The Oncologist

http://theoncologist.alphamedpress.org/content/ear...

• This retrospective study of 483 patients at two institutions (Yale and MD Anderson Cancer Centers) reports outcomes among patients with de novo stage IV HER2-positive breast cancer treated with HER2-directed therapy. Median OS was 5.5 years. Among the 13% of patients who achieved no evidence of disease (NED) status, PFS and OS rates at 5 years were 100% and 98%, respectively. Patients often required resection of solitary metastases to achieve NED status.
• Notably, results were maintained at 10 years.
• NED patients more frequently had solitary metastasis and surgery to resect cancer.
• NED status and estrogen receptor positive status were associated with prolonged OS.

{This is very reassuring news for relevant populations!}

illimae

Thanks Lumpie, great read. Also, I was delighted to see that the Oncologist article was written (in part) by my MO (Murthy) 😀

marijen

Not breaking news, Aug.2017

Alternative Medicine Kills Cancer Patients, Study Finds

https://www.realclearscience.com/quick_and_clear_s...

Lumpie

Circulating MicroRNAs in Breast Cancer as an Indicator of Clinical Response to Neoadjuvant Chemotherapy

https://www.practiceupdate.com/C/72254/56?elsca1=e...

Published in Cancer Medicine

• This study looked at the association of plasma circulating microRNA with response to neoadjuvant chemotherapy in 109 patients with operable or locally advanced breast cancer.
• Several early markers were identified for predicting response to neoadjuvant chemotherapy in HR+/HER2− disease.
• ...dynamics of circulating miRNAs might help predict clinical response to neoadjuvant chemotherapy in breast cancer.

Frisky

Maryjean...are you aware that 99% of stage four cancer patients will NOT survive the five years mark?

And that 30% of stage one and two patients that undergo the recommended treatment and take hormonal medications for the next 10 years will be diagnosed stage four regardless??

Are you aware that during the latest ASCO meeting it was decided that stage one and two should not undergo the typical protocols.

More interesting still, do you know that all the medications we have to take are unreliable and unpredictable for the same type of cancers as classified by their own scientific methods? At our best institutions?

Isn't the definition of scientific an observable repeatable event? Well there's nothings scientific or predictable with cancer medications.. what's predictable is that they wreak what's still working in our bodies and that most of them are ancerogenic. Look up tamoxifen warning sheet, it's at the top of a five pages list of health problems.

I'm not defending the alternative cures here, as they too seem to miss the mark by a mile. But why call them quacks when the other side have the highest rate of failure while being paid exhurbitant amount of money and receiving all the grants and reasearch money?

Just because we don't have viable choices doesn't make what we do have less ridiculous.

let's hope that both sides can start thinking outside the box and can provide real answers and solutions to a diseases that affects and will likely kill 1in 2 Americans over their lifetime.

marijen

I’m sorry if I upset you Miaomix, it’s only a study and I think it is about ONLY doing alternative treatment. There isn’t much rhyme or reason to the treatments we are given. Yes I do know 30% go on to stage IV and Stage IV does not have a good survival rate. I did not have chemo and am an antihormonal dropout. Thank you for your informative post.

If we knew what it was we were doing, it would not be called research, would it? —Albert Einstein

KathyL624

Can you explain what happened at ASCO regarding Stage 1 and 2